ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1822

Pharmacokinetics of the Selective B-Cell Lymphoma-2 (Bcl-2) Inhibitor, ABT-199, in Female Subjects with Systemic Lupus Erythromatosus

Mukul Minocha1, Shekman Wong2, Jiewei Zeng2, Peng Lu3, Jeroen Medema2 and Ahmed Othman4, 1Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL, 2AbbVie Inc., North Chicago, IL, 3AbbVie Inc., Worcester, MA, 4AbbVie, North Chicago, IL

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: B cells, pharmacokinetics and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 9, 2015

Session Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Selective Inhibition of Bcl-2 pathway may offer clinical efficacy in Systemic Lupus Erythromatosus (SLE) by restoring apoptosis in autoreactive cells, which may lead to immune response resolution. ABT-199 is an orally bioavailable, selective Bcl-2 inhibitor currently under evaluation for treatment of SLE and several oncology indications. This work characterized the pharmacokinetics of ABT-199 in female subjects with SLE following single and multiple dosing

Methods: Single escalating oral doses (10, 30, 90, 180, 300, 500 mg or matching placebo, total 48 subjects) and multiple escalating oral doses (30, 60, 120, 240, 400, 600 mg or matching placebo, total 50 subjects) of ABT-199 were evaluated. The multiple dose evaluation consisted of two cycles each including once daily dosing under non-fasting conditions for 7 days followed by a 21 day washout period. Both evaluations followed randomized, double-blind, placebo-controlled designs (3:1 active: placebo). Serial blood samples were collected for characterization of ABT-199 pharmacokinetics.

Results: ABT-199 followed bi-exponential disposition with peak plasma concentrations observed within 4 to 8 hours post dose. Steady-state exposures were achieved within 4 days of dosing. ABT-199 exposure did not deviate significantly from dose proportionality over the evaluated dose range and the median steady-state accumulation ratio was 1.1 to 1.5. ABT-199 terminal elimination half-life ranged from 7 to 17 hours and the effective half-life, calculated based on Cmax to Ctrough ratio at steady state, was 9 to 11 hours. The fraction of ABT-199 dose eliminated unchanged in urine was negligible

Conclusion: ABT-199 displayed favorable pharmacokinetic profile in female subjects with SLE that warrants further clinical evaluations


Disclosure: M. Minocha, AbbVie, 1,AbbVie, 3; S. Wong, AbbVie, 3; J. Zeng, AbbVie, 1,AbbVie, 3; P. Lu, AbbVie, 1,AbbVie, 3; J. Medema, AbbVie, 1,AbbVie, 3; A. Othman, AbbVie, 1,AbbVie, 3.

To cite this abstract in AMA style:

Minocha M, Wong S, Zeng J, Lu P, Medema J, Othman A. Pharmacokinetics of the Selective B-Cell Lymphoma-2 (Bcl-2) Inhibitor, ABT-199, in Female Subjects with Systemic Lupus Erythromatosus [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/pharmacokinetics-of-the-selective-b-cell-lymphoma-2-bcl-2-inhibitor-abt-199-in-female-subjects-with-systemic-lupus-erythromatosus/. Accessed February 24, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pharmacokinetics-of-the-selective-b-cell-lymphoma-2-bcl-2-inhibitor-abt-199-in-female-subjects-with-systemic-lupus-erythromatosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.